Project Grant R41CA298398
Award Date 9/1/25
Completion Date 8/31/26
Dollars Obligated $400K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $1,021,347 to Vigilant Laboratories LLC to develop a low-cost, point-of-care early detection test for oral cancer in low-resource settings. The key products to be delivered include: Prototypes of test strips for three biomarkers (CD44, total protein, and p16) to enable a commercializable point-of-care test. Vigilant Laboratories will work with a manufacturing partner,...
- This National Science Foundation (NSF) Cooperative Agreement award of $1,244,392 to Oraliva, Inc. under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program will fund the development of a portable single-cell cytology and predictive analysis platform for the early detection of epithelial cancers. The project aims to create an accurate and efficient, AI-linked point-of-care cancer diagnostic technology that can enable early-stage detection, ultimately reducing the economic...
- The National Cancer Institute (NCI) awarded a $306,872 Project Grant under the Cancer Detection and Diagnosis Research Federal Grant Program (CFDA 93.394) to Flexbiotech Inc. located in Scottsdale, AZ. The grant funding will support the development and validation of a novel, portable isothermal nucleic-acid test called SPRINT-HPV. This test is designed to simultaneously detect HPV16, HPV18, and nine other high-risk HPV subtypes from cervical fluid, specifically targeting point-of-care use in...
- The National Science Foundation awarded a $275,000 Project Grant to Oraliva, Inc. under the Technology, Innovation, and Partnerships program to develop a portable, programmable single cell cytology platform for the early detection of epithelial cancers. The platform will combine microfluidics and artificial intelligence to classify potentially cancerous tissue in near real-time through multiparameter single-cell analysis and automated evaluation. The objectives are to link different clinical...
- The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $1,414,853 Project Grant under the Oral Diseases and Disorders Research program (CFDA 93.121) to Innotech Precision Medicine, Inc., a woman-owned small business, to develop RECOGNIZE-OPSCC. This saliva-based, point-of-care diagnostic test aims to provide rapid, non-invasive, and accurate detection of oropharyngeal squamous cell carcinoma (OPSCC). The project integrates an AI-enabled, ultraportable device with an...
- The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $1,178,476 Project Grant under the Oral Diseases and Disorders Research federal grant program (CFDA 93.121) to Oraliva, Inc., a technology company in Durham, North Carolina. The purpose of this 2-year project, with a completion date of March 31, 2027, is to develop an AI-linked cytomics-on-a-chip technology to enable near real-time identification and management of oral lichenoid lesions in primary care settings. This...
- This federal Project Grant award of $317,420 from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to develop and validate a patient-ready callascope device for cervical imaging and cancer prevention in low- and middle-income countries (LMICs). The primary focus is on creating point-of-care solutions for screening, diagnosis, and treatment that can be delivered by community health workers and midwives, thereby increasing access to care. Key...
- This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $371,161 to develop advanced AI-based risk models for cervical cancer screening in low-resource settings. The project aims to leverage time-series imaging data and self-supervised learning to enhance the diagnostic accuracy of automated visual evaluation (AVE) models. The goal is to create a comprehensive risk stratification system that combines imaging data, HPV...
- This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $349,808 to Oncurie Inc. to continue development of a novel targeted radiopharmaceutical for imaging and potential therapy of ovarian cancer. The compound leverages the folate receptor overexpression in ovarian tumors to enable precision imaging, with future plans to incorporate cytotoxic radionuclides for targeted therapy. During the Phase I award period from Sep 2024...
- This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $399,998 to Darwin Biosciences, Inc. to develop a low-cost, handheld, and non-invasive lung cancer screening device for use in low-resource settings. The device will incorporate sample collection, nucleic acid biomarker detection via isothermal recombinase polymerase amplification, and a visual readout on lateral flow strips. This work builds on Darwin Biosciences' prior...